Innovative strategies for T cell engagers for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• T cell engagers (TCEs) represent a significant advancement in cancer immunotherapy, redirecting T cells to eliminate tumor cells.
• Current TCE applications face limitations including cytokine release syndrome (CRS), on-target off-tumor toxicity, and overcoming tumor immunosuppression in various cancer types.

Purpose of the Study:

• This review examines recent innovations in TCE design focused on enhancing safety and therapeutic efficacy.
• The goal is to explore strategies that mitigate current clinical challenges and expand the utility of TCEs.

Main Methods:

• Innovations discussed include optimizing TCE geometry for immune synapse formation and fine-tuning anti-CD3/TCR domain affinity to reduce CRS.
• Logic-gated approaches, such as dual-targeting and conditional activation by tumor microenvironment factors, are explored to minimize off-tumor toxicity.
• The review also considers the integration of costimulatory signaling to boost efficacy.

Main Results:

• Optimized designs and logic-gated strategies show potential in reducing CRS and on-target off-tumor toxicities.
• These advancements may lead to deeper and more durable responses in both hematological and solid tumors.
• Leveraging costimulatory signals could further enhance treatment effectiveness.

Conclusions:

• The next generation of TCEs is poised to overcome limitations of current therapies, expanding their therapeutic window and enabling combination treatments.
• TCEs are expected to become a foundational element of cancer immunotherapy, improving outcomes for a wider patient population.